

Avi Leader

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8256131/publications.pdf>

Version: 2024-02-01

48
papers

641
citations

623188

14
h-index

610482

24
g-index

49
all docs

49
docs citations

49
times ranked

1082
citing authors

#	ARTICLE	IF	CITATIONS
1	Implementation of a Novel Protocol for Preventing Venous Thromboembolism in Otolaryngology Patients. <i>Otolaryngology - Head and Neck Surgery</i> , 2022, 166, 297-304.	1.1	3
2	Effectiveness of the BNT162b2mRNA COVID-19 vaccine in patients with hematological neoplasms in a nationwide mass vaccination setting. <i>Blood</i> , 2022, 139, 1439-1451.	0.6	58
3	Previously undiagnosed cancer in patients with arterial thrombotic events – A population-based cohort study. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 635-647.	1.9	2
4	Exacerbation of immune thrombocytopenia following initial and booster vaccination with Pfizer-BioNTech COVID-19 vaccine. <i>Platelets</i> , 2022, 33, 781-786.	1.1	6
5	Cancer-associated venous thromboembolism in Israel: Incidence, risk factors, treatment, and health care utilization in a population based cohort study. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, .	1.0	1
6	Thrombosis and bleeding in hematological malignancy. <i>Best Practice and Research in Clinical Haematology</i> , 2022, 35, 101353.	0.7	7
7	D-dimer and risk for thrombosis in adults with newly diagnosed acute lymphoblastic leukemia. <i>Blood Advances</i> , 2022, 6, 5146-5151.	2.5	7
8	EHA Guidelines on Management of Antithrombotic Treatments in Thrombocytopenic Patients With Cancer. <i>HemaSphere</i> , 2022, 6, e750.	1.2	29
9	Anticoagulation in patients with atrial fibrillation, thrombocytopenia and hematological malignancy. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 52, 590-596.	1.0	4
10	Challenges and Advances in Managing Thrombocytopenic Cancer Patients. <i>Journal of Clinical Medicine</i> , 2021, 10, 1169.	1.0	14
11	Venous thromboembolism incidence and risk assessment in lung cancer patients treated with immune checkpoint inhibitors. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1250-1258.	1.9	34
12	Characteristics and outcomes of patients on concurrent direct oral anticoagulants and targeted anticancer therapies – TacDOAC registry: Communication from the ISTH SSC Subcommittee on Hemostasis and Malignancy. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2068-2081.	1.9	23
13	Targeted therapies for immune thrombocytopenic purpura: a meta-analysis of randomized controlled trials. <i>Annals of Hematology</i> , 2021, 100, 2879-2887.	0.8	3
14	Between a Rock and a Hard Place: Paraproteinemia Associated with Chronic Myeloid Leukemia. <i>Blood</i> , 2021, 138, 1488-1488.	0.6	0
15	Anticoagulant and antiplatelet treatment in cancer patients with thrombocytopenia. <i>Thrombosis Research</i> , 2020, 191, S68-S73.	0.8	7
16	Health-Related Quality of Life in Patients with Chronic Myeloid Leukemia Treated with First- Versus Second-Generation Tyrosine Kinase Inhibitors. <i>Journal of Clinical Medicine</i> , 2020, 9, 3417.	1.0	4
17	Management and Outcome of Venous Thrombosis in Patients with Myeloproliferative Neoplasms: Data from the Israeli MPN Working Group. <i>Acta Haematologica</i> , 2020, 144, 1-8.	0.7	0
18	Intracranial hemorrhage with direct oral anticoagulants in patients with brain metastases. <i>Blood Advances</i> , 2020, 4, 6291-6297.	2.5	28

#	ARTICLE	IF	CITATIONS
19	Anticoagulation in thrombocytopenic patients with hematological malignancy: A multinational clinical vignette-based experiment. <i>European Journal of Internal Medicine</i> , 2020, 77, 86-96.	1.0	7
20	Risk Assessment and Management of Venous Thromboembolism in Cancer Patients: A Population-Based Cohort Study. <i>Blood</i> , 2020, 136, 27-27.	0.6	0
21	D-Dimer As a Predictor of Thrombotic Events during Early Acute Lymphoblastic Leukemia Therapy. <i>Blood</i> , 2020, 136, 5-6.	0.6	0
22	Bosutinib, dasatinib, imatinib, nilotinib, and ponatinib differentially affect the vascular molecular pathways and functionality of human endothelial cells. <i>Leukemia and Lymphoma</i> , 2019, 60, 189-199.	0.6	43
23	Hemophagocytic lymphohistiocytosis as a harbinger of aggressive lymphoma: a case series. <i>International Journal of Hematology</i> , 2019, 109, 553-562.	0.7	14
24	Computed Tomography Findings Associated With 30-Day Mortality in Patients With Malignant Superior Vena Cava Syndrome. <i>Journal of Computer Assisted Tomography</i> , 2019, 43, 912-918.	0.5	2
25	Mean platelet volume and clinical outcomes of patients with chest pain discharged from internal medicine wards. <i>Coronary Artery Disease</i> , 2019, 30, 455-460.	0.3	0
26	Postpartum Hemophagocytic Lymphohistiocytosis: A New Entity Is Born. <i>Acta Haematologica</i> , 2019, 141, 61-62.	0.7	2
27	Managing Anti-Platelet Therapy in Thrombocytopenic Patients with Haematological Malignancy: A Multinational Clinical Vignette-Based Experiment. <i>Thrombosis and Haemostasis</i> , 2019, 119, 163-174.	1.8	3
28	Thrombosis, anticoagulation and outcomes in malignant superior vena cava syndrome. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 47, 121-128.	1.0	11
29	Venous thromboembolism (VTE) in patients with ALK-rearranged non-small cell lung cancer (ALK-LC): A population-based cohort.. <i>Journal of Clinical Oncology</i> , 2019, 37, 6608-6608.	0.8	1
30	Mean platelet volume and risk of thrombotic and bleeding complications in patients with Philadelphia chromosome negative myeloproliferative neoplasms. <i>Blood Coagulation and Fibrinolysis</i> , 2018, 29, 288-293.	0.5	6
31	Identifying Tyrosine Kinase Inhibitor Nonadherence in Chronic Myeloid Leukemia: Subanalysis of TAKE-IT Pilot Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e351-e362.	0.2	4
32	Effect of Adherence-enhancing Interventions on Adherence to Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia (TAKE-IT): A Quasi-experimental Pre-Post Intervention Multicenter Pilot Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e449-e461.	0.2	13
33	Morbidity and mortality after fragility hip fracture surgery in patients receiving vitamin K antagonists and direct oral anticoagulants. <i>Thrombosis Research</i> , 2018, 166, 106-112.	0.8	39
34	Adult pre B-cell acute lymphoblastic leukemia with unusually large proportion of bone marrow CD45 bright/high SS ^c blasts. <i>Cytometry Part B - Clinical Cytometry</i> , 2017, 92, 161-164.	0.7	4
35	The Effect of Combined Aspirin and Clopidogrel Treatment on Cancer Incidence. <i>American Journal of Medicine</i> , 2017, 130, 826-832.	0.6	48
36	Switching-On Adherence in Chronic Myeloid Leukemia. <i>Acta Haematologica</i> , 2017, 138, 138-139.	0.7	0

#	ARTICLE	IF	CITATIONS
37	Ponatinib reduces viability, migration, and functionality of human endothelial cells. <i>Leukemia and Lymphoma</i> , 2017, 58, 1455-1467.	0.6	46
38	First line treatment with newer tyrosine kinase inhibitors in chronic myeloid leukemia associated with deep and durable molecular response – systematic review and meta-analysis. <i>Acta Oncologica</i> , 2016, 55, 1077-1083.	0.8	11
39	Prevalence and Significance of Unrecognized Renal Dysfunction in Patients with Acute Coronary Syndrome. <i>American Journal of Medicine</i> , 2016, 129, 187-194.	0.6	15
40	The role of protein disulfide isomerase in the post-ligation phase of β_2 integrin-dependent cell adhesion. <i>Thrombosis Research</i> , 2015, 136, 1259-1265.	0.8	10
41	Tyrosine kinase inhibitor associated vascular toxicity in chronic myeloid leukemia. <i>Cardio-Oncology</i> , 2015, 1, 5.	0.8	38
42	Hypertension in cancer patients treated with anti-angiogenic based regimens. <i>Cardio-Oncology</i> , 2015, 1, 6.	0.8	25
43	Anticoagulation Therapy for Venous Thrombotic Events in Patients with Myeloproliferative Neoplasms. <i>Blood</i> , 2015, 126, 4081-4081.	0.6	0
44	Thyrotropin Levels Within the Lower Normal Range Are Associated With an Increased Risk of Hip Fractures in Euthyroid Women, But Not Men, Over the Age of 65 Years. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 2665-2673.	1.8	46
45	Adherence-Related Issues in Adolescents and Young Adults with Hematological Disorders. <i>Acta Haematologica</i> , 2014, 132, 348-362.	0.7	13
46	The Role of the Newer Tyrosine Kinase Inhibitors As First Line Treatment in Chronic Phase Chronic Myeloid Leukemia – an Updated Meta-Analysis. <i>Blood</i> , 2014, 124, 4563-4563.	0.6	0
47	The Role Of Protein Disulfide Isomerase In The Post-Ligation Phase Of β_2 Integrin-Dependent Cell Adhesion. <i>Blood</i> , 2013, 122, 2307-2307.	0.6	0
48	An Open-Label Study Adding Creatine Monohydrate to Ongoing Medical Regimens in Patients with the Fibromyalgia Syndrome. <i>Annals of the New York Academy of Sciences</i> , 2009, 1173, 829-836.	1.8	9